<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516499</url>
  </required_header>
  <id_info>
    <org_study_id>NSP001</org_study_id>
    <nct_id>NCT04516499</nct_id>
  </id_info>
  <brief_title>Neurofilament Surveillance Project (NSP)</brief_title>
  <official_title>Remote Blood Biomarker Monitoring in Frontotemporal Lobar Degeneration: Neurofilament Surveillance Project (NSP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Bluefield Project to Cure Frontotemporal Dementia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Bluefield Project to Cure Frontotemporal Dementia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a biomarker study designed to collect and analyze blood specimens from individuals&#xD;
      carrying known familial frontotemporal lobar degeneration (f-FTLD) mutations compared to a&#xD;
      control group of individuals without known f-FTLD mutations. The NSP is an ancillary study to&#xD;
      the ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration&quot; (ALLFTD) study,&#xD;
      NCT04363684. More information can be found at https://www.allftd.org/.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Frontotemporal Lobar Degeneration (FTLD), a group of clinically heterogeneous&#xD;
      neurodegenerative diseases characterized by progressive deterioration of the frontal and&#xD;
      temporal cortices as well as basal ganglia and brainstem structures, is a common cause of&#xD;
      neurodegenerative dementia in people who are less than 60 years old at onset. It is uniformly&#xD;
      fatal. FTLD is a rare disease, with an estimated prevalence of approximately 5-22 per&#xD;
      100,000. There are no approved treatments, however several investigational agents are in&#xD;
      human trials and a variety of novel agents are poised to enter human development. Experience&#xD;
      from other neurodegenerative diseases suggests that potential disease modifying treatments&#xD;
      are most likely to be efficacious if initiated before the onset of symptoms.&#xD;
&#xD;
      Approximately 25% of FTLD cases are familial (f-FTLD) and due to autosomal dominant mutations&#xD;
      in one of three genes: C9orf72, progranulin (GRN) or microtubule associated protein tau&#xD;
      (MAPT). Many of the new therapies entering the clinic directly target one of these genetic&#xD;
      causes and raise the possibility that the clinical features of FTLD could be delayed or&#xD;
      prevented in these individuals if an efficacious therapy was initiated prior to the onset of&#xD;
      symptoms. The major barrier to determining efficacy of novel therapeutic agents for f-FTLD in&#xD;
      such prevention trials is the lack of an endpoint that can indicate therapeutic efficacy&#xD;
      prior to the onset of symptoms. Our preliminary data strongly suggest that plasma&#xD;
      neurofilament light chain (NfL) could serve as such a biomarker.&#xD;
&#xD;
      This non-interventional study is in preparation for pivotal clinical trials. Up to 335&#xD;
      participants will provide blood remotely via visits from traveling mobile research nurses&#xD;
      four times a year for three years (4355 samples total) to enable the observation of&#xD;
      peripheral NfL levels longitudinally during disease onset and progression, with the ultimate&#xD;
      goal of qualifying plasma NfL as an endpoint for f-FTLD prevention trials. The NSP study is&#xD;
      an ancillary study to ALLFTD, and biomarker data collected in the NSP will be correlated with&#xD;
      ALLFTD clinical data. More information on the NSP study may be found at&#xD;
      https://www.allftd.org/nsp.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neurofilament Light Chain Levels</measure>
    <time_frame>36 months</time_frame>
    <description>To determine the longitudinal stability of plasma neurofilament light chain (NfL) measured every 3 months for 36 months in individuals at-risk for symptomatic FTLD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intersubject variability of plasma NfL measurements</measure>
    <time_frame>36 months</time_frame>
    <description>Concentration of plasma neurofilament light chain protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Logistics measure</measure>
    <time_frame>36 months</time_frame>
    <description>Participant compliance with scheduled remote blood collection and sample processing</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical and MRI correlates</measure>
    <time_frame>36 months</time_frame>
    <description>To evaluate ALLFTD collected clinical and magnetic resonance imaging (MRI) neuroimaging correlates with plasma NfL levels in asymptomatic and symptomatic f-FTLD mutation carriers</description>
  </other_outcome>
  <other_outcome>
    <measure>Other biomarker evaluation</measure>
    <time_frame>36 months</time_frame>
    <description>To measure other novel blood biomarkers of neurodegeneration yet to be determined</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">335</enrollment>
  <condition>Frontotemporal Dementia</condition>
  <condition>Frontotemporal Lobar Degeneration</condition>
  <condition>FTD-GRN</condition>
  <arm_group>
    <arm_group_label>f-FTLD mutation carriers</arm_group_label>
    <description>All participants must be from a family with f-FTLD mutations. The f-FTLD mutation carrier group members will have their genetic status tested and included in this group if a f-FTLD mutation is observed. Participants do not need to know or be told their genetic status.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-mutation carriers from families with f-FTLD mutations</arm_group_label>
    <description>All participants must be from a family with f-FTLD mutations. The non-mutation carrier group members will have their genetic status tested and included in this group if they do not have a f-FTLD mutation. Participants do not need to know or be told their genetic status.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma will be extracted from participant's whole blood. The plasma will be analyzed for the&#xD;
      levels of neurofilament light chain and other potential biomarkers.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study is an ancillary study to ALLFTD. Thus, all NSP participants will be recruited&#xD;
        directly from the longitudinal arm of ALLFTD.&#xD;
&#xD;
        Roughly equivalent numbers of participants will be enrolled from each of the following&#xD;
        groups:&#xD;
&#xD;
          -  Members of families with known mutations in C9orf72&#xD;
&#xD;
          -  Members of families with known mutations in GRN&#xD;
&#xD;
          -  Members of families with known mutations in MAPT&#xD;
&#xD;
        Although participant must be from a family with a known mutation, the participant&#xD;
        themselves need not know their personal mutation status.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female&#xD;
&#xD;
          2. Ages 18-85&#xD;
&#xD;
          3. Provision of signed and dated informed consent form&#xD;
&#xD;
          4. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          5. Is enrolled in the longitudinal arm of ALLFTD&#xD;
&#xD;
          6. Is a member of a family with a known mutation in C9orf72, GRN or MAPT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any permanent contra-indication to repeated blood draws, such as poor venous access.&#xD;
&#xD;
          2. Any conditions or circumstances which, in the opinion of the investigator, would not&#xD;
             allow participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Boxer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bradley Boeve, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Howie Rosen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Mitic, PhD</last_name>
    <role>Study Director</role>
    <affiliation>The Bluefield Project to Cure Frontotemporal Dementia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Acuna-Narvaez</last_name>
    <phone>6503801191</phone>
    <email>rachel.acuna-narvaez@bluefieldproject.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise Ong</last_name>
      <phone>415-514-5751</phone>
      <email>Elise.Ong@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Boxer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Howie Rosen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Reineke</last_name>
      <phone>904-953-4107</phone>
      <email>Reineke.Maricica@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Neill Graff-Radford, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Fishman</last_name>
      <phone>410-502-5816</phone>
      <email>ann.fishman@jhu.edu</email>
    </contact>
    <investigator>
      <last_name>Chiadi Onyike, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Krahn</last_name>
      <email>ekrahn@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Brad Dickerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tyler Kolander</last_name>
      <phone>507-284-9295</phone>
      <email>Kolander.Tyler@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Bradley Boeve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Nolte</last_name>
      <email>nolte.tina@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Nupur Ghoshal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masood Manoochehri</last_name>
      <phone>212-305-5710</phone>
      <email>mm2626@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Edward Huey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Balgenorth</last_name>
      <email>Yvonne.Balgenorth@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Lauren Massimo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>C9orf72</keyword>
  <keyword>GRN</keyword>
  <keyword>MAPT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Frontotemporal Lobar Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Please consult with ALLFTD regarding individual participant data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

